间皮素靶向227Th偶联物联合DNA损伤应答抑制剂在卵巢癌异种移植模型中的协同效应
该研究评估了间皮素靶向的α射线治疗药物MSLN-TTC(BAY 2287411)与多种DNA损伤应答(DDR)抑制剂联用的效果。体外实验显示所有测试的DDR抑制剂均与MSLN-TTC产生协同活性,其中ATR抑制剂和PARP抑制剂增效最强。在OVCAR-3和OVCAR-8卵巢癌异种移植模型中,MSLN-TTC联合ATR抑制剂在单药无效剂量下仍表现出协同抗肿瘤活性。
要点
- MSLN-TTC与DDR抑制剂联用在体外均显示协同细胞毒活性。
- ATR抑制剂和PARP抑制剂对MSLN-TTC的增效作用最强。
- 体内实验中MSLN-TTC联合ATR抑制剂在单药无效剂量下仍具协同抗肿瘤活性。
核心结论
- 数据支持将MSLN-TTC与DDR抑制剂联用作为间皮素阳性卵巢癌的新治疗策略。
研究设计与样本
- 体外细胞毒性实验:MSLN-TTC联合ATM、ATR、DNA-PK和PARP1/2抑制剂。
- 体内抗肿瘤疗效:人卵巢癌OVCAR-3和OVCAR-8异种移植模型(裸鼠)。
主要发现
- 体外所有测试的DDR抑制剂与MSLN-TTC联用均观察到协同活性。
- ATR抑制剂和PARP抑制剂诱导的效力增加最强。
- 体内MSLN-TTC联合ATR抑制剂在单药无效剂量下显示协同抗肿瘤活性。
临床怎么用
- 为间皮素阳性卵巢癌患者提供MSLN-TTC联合DDR抑制剂的潜在治疗思路。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Targeted 227Th conjugates (TTCs) represent a new class of therapeutic radiopharmaceuticals for targeted α-therapy. They comprise the α-emitter 227Th complexed to a 3,2-hydroxypyridinone chelator conjugated to a tumor-targeting monoclonal antibody. The high energy and short range of the α-particles induce antitumor activity, driven by the induction of complex DNA double-strand breaks. We hypothesized that blocking the DNA damage response (DDR) pathway should further sensitize cancer cells by inhibiting DNA repair, thereby increasing the response to TTCs. Methods: This article reports the evaluation of the mesothelin (MSLN)-TTC conjugate (BAY 2287411) in combination with several DDR inhibitors, each of them blocking different DDR pathway enzymes. MSLN is a validated cancer target known to be overexpressed in mesothelioma, ovarian, lung, breast, and pancreatic cancer, with low expression in normal tissue. In vitro cytotoxicity experiments were performed on cancer cell lines by combining the MSLN-TTC with inhibitors of ataxia telangiectasia mutated, ataxia telangiectasia and Rad3-related (ATR), DNA-dependent protein kinase, and poly[adenosine diphosphate ribose] polymerase (PARP) 1/2. Further, we evaluated the antitumor efficacy of the MSLN-TTC in combination with DDR inhibitors in human ovarian cancer xenograft models. Results: Synergistic activity was observed in vitro for all tested inhibitors (inhibitors are denoted herein by the suffix "i") when combined with MSLN-TTC. ATRi and PARPi appeared to induce the strongest increase in potency. Further, in vivo antitumor efficacy of the MSLN-TTC in combination with ATRi or PARPi was investigated in the OVCAR-3 and OVCAR-8 xenograft models in nude mice, demonstrating synergistic antitumor activity for the ATRi combination at doses demonstrated to be nonefficacious when administered as monotherapy. Conclusion: The presented data support the mechanism-based rationale for combining the MSLN-TTC with DDR inhibitors as new treatment strategies in MSLN-positive ovarian cancer.
引用
- Wickstroem K, Hagemann UB, Cruciani V, et al. Synergistic Effect of a Mesothelin-Targeted 227Th Conjugate in Combination with DNA Damage Response Inhibitors in Ovarian Cancer Xenograft Models. J Nucl Med. 2019. PMID: 30850485. doi:10.2967/jnumed.118.223701
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。